A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


January 7, 2013

HIV Med Selzentry (Maraviroc) Found to Fight Staph Infection

The HIV antiretroviral Selzentry (maraviroc) combats the potentially lethal pathogen Staphylococcus aureus, the bacterium that causes staph infections, according to research from the New York University School of Medicine, redOrbit reports. Staph infections, which are the cause of hundreds of thousands of hospital admissions each year in the United States, are increasingly antibiotic-resistant. Publishing their findings in the journal Nature, the researchers discovered that a toxin called LukED that the bacterium excretes latches onto the same CCR5 coreceptor on the CD4 cell that HIV typically uses in order to gain entry. LukED then pierces holes through the CD4’s membrane, killing the cell.

Because Selzentry blocks the ability of the toxin to latch onto the CCR5’s coreceptor, it has the potential to thwart staph’s assault on the immune system. When the researchers treated CD4 cells with the antiretroviral in a laboratory setting, the drug totally blocked the toxic effects of LukED, which comes from a family known as leukotoxins. Researchers then examined the effects of CCR5 coreceptor inhibition in mice. Nearly all mice exposed to staph containing LukED died, while all those mice the scientists had genetically engineered to lack the CCR5 coreceptor survived the infection.

“The goal in blocking the toxin with maraviroc or similar agents is to give the upper hand to the immune system to better control the [staph] infection,” lead researcher Victor J. Torres, PhD, assistant professor of microbiology at NYU School of Medicine, said in a release.

The scientists hope the research will advance to human clinical trials.

To read the study abstract, click here

For the redOrbit story, click here.

Search: Selzentry, maraviroc, HIV, antiretroviral, staph infection, Staphylococcus aureus, bacterium, New York University School of Medicine, redOrbit, toxin, LukED, CCR5, coreceptor, CD4, Victor Torres.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.